Compare BDSX & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDSX | DTIL |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.0M | 97.7M |
| IPO Year | 2020 | 2019 |
| Metric | BDSX | DTIL |
|---|---|---|
| Price | $18.75 | $4.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $32.50 | ★ $60.00 |
| AVG Volume (30 Days) | 129.1K | ★ 159.9K |
| Earning Date | 05-21-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 106.52 |
| EPS | ★ N/A | N/A |
| Revenue | $88,499,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $23.35 | N/A |
| Revenue Next Year | $19.33 | $34.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.08 | N/A |
| 52 Week Low | $0.25 | $3.53 |
| 52 Week High | $17.40 | $8.82 |
| Indicator | BDSX | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 81.53 | 61.19 |
| Support Level | $6.33 | $4.17 |
| Resistance Level | N/A | $4.61 |
| Average True Range (ATR) | 1.80 | 0.27 |
| MACD | 0.39 | 0.09 |
| Stochastic Oscillator | 97.27 | 75.21 |
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.